Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q3FY2306-01-2023
06-01-2023
Gland Pharma Ltd - 543245 - Board Meeting Intimation for The Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2023 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 202206-01-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on proposed acquisition of Cenexi06-01-2023
Gland Pharma Ltd - 543245 - Conclusion Of US FDA Inspection At Dundigal Facility, Hyderabad
Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad04-01-2023
Hold Gland Pharma; target of Rs 1689: Sharekhan
Sharekhan recommended Hold rating on Gland Pharma with a target price of Rs 1689 in its research report dated December 29, 2022.30-12-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor meeting26-12-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meetings15-12-2022
Fosun knocks on doors of Advent Intl, Baring PE, Bain Capital for Gland Pharma buyout: Report
As per BSE filing, Fosun International has a controlling stake of 57.86 percent in Hyderabad-based Gland Pharma13-12-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meetings12-12-2022